The effects of dopamine receptor agents on naloxone-induced jumping behaviour in morphine-dependent mice

European Journal of Pharmacology

Volumn 451, Issue 3, 2002, Pages 287-293

  Zarrindast, Mohammad Reza ^a   Habibi, Manijeh ^a   Borzabadi, Shokofeh ^a   Fazli Tabaei, Soheila ^b   Hossein Yahyavi, Seyed ^b   Rostamin, Parvin ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c KHARAZMI UNIVERSITY   (Iran)

Author keywords

(Mouse); Dopamine receptor agent; Jumping; Morphine; Naloxone

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BROMOCRIPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MORPHINE; NALOXONE; QUINPIROLE; SULPIRIDE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; HYPERACTIVITY; JUMPING; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; MALE; MICE; MORPHINE DEPENDENCE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS;

EID: 0037144236     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02149-0     Document Type: Article

References (43)

1. Altar C.A., O'Neill S., Walter R.R., Marshar G.F. Brain dopamine and serotonin receptor sites revealed by digital subtraction autoradiography. Science. 228:1985;597-600.
2. Bach N.J., Kornfeld E.C., Jones N.D., Chaney M.O., Doram D.E., Pschal J.W., Clemens J.A., Smalsting E.B. Bicyclic and tricyclic ergolin partial structures. Rigid 3-(2-aminoethyl) pyrroles and 3- and 4-(2-aminoethyl)pyrazoles and dopamine agonists. J. Med. Chem. 23:1980;481-491.
3. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administration behaviour. Pharmacol. Rev. 46:1994;293-324.
4. Bilsky E.J., Montegut M.J., Delong C.L., Reid L.D. Opioidergic modulation of cocaine conditioned place preference. Life Sci. 50:1992;85-90.
5. Bourin M. Cholecystokinin receptor agonists block the jumping behaviour precipitated in morphine-dependent mice by naloxone. Eur. Neuropsychopharmacol. 9:1999;37-43.
6. Costal B., Fortune D.H., Hui S.C.G., Naylor R.J. Neuroleptic antagonism of the motor inhibitory effect of apomorphine within the nucleus accumbens: drug interaction at presynaptic receptors? Eur. J. Pharmacol. 63:1980;347-358.
7. Creese I., Sibley D.R., Hamblin M.W., Leff S.E. The classification of dopamine receptor: relationship to radioligand binding. Annu. Rev. Neurosci. 6:1983;43-71.
8. Diana M., Muntoni A.L., Pistis M., Melis M., Gessa G.L. Lsting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal. Eur. J. Neurosci. 11:1999;1037-1041.
9. Di Chiara G., Porceddu M.L., Vargiu L., Argiolas A., Gessa G.L. Evidence for dopamine receptors mediating sedation in mouse brain. Nature. 264:1976;564-567.
10. 3H]SCH23390. Eur. J. Pharmacol. 108:1985;323-325.
11. Druhan J.P., Walters C.L., Aston-Jones G. Behavioral activation induced by D(2)-like receptor stimulation during opiate withdrawal. J. Pharmacol. Exp. Ther. 294:2000;531-538.
12. 3H]SKF38393 in the rat brain and spinal cord. Comparison with the distribution of D2 dopamine receptors. Neuroscience. 19:1986;125-137.
13. Dumbrille-Ross A., Niznik H., Seeman P. Separation of dopamine D-1 and D-2 receptors. Eur. J. Pharmacol. 110:1985;151-152.
14. El-Kadi A.O.S., Sharif S.I. The role of dopamine in the expression of morphine withdrawal. Gen. Pharmacol. 30:1998;499-506.
15. Georges F., Stinus L., Bloch B., Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur. J. Neurosci. 11:1999;481-490.
16. Givelli O., Bunzow J.R., Grandy D.K. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. 32:1993;281-307.
17. Hyttel J. Functional evidence for selective dopamine D-1 receptor blockade by SCH23390. Neuropharmacology. 23:1984;1395-1401.
18. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., Korduba C.A. A potential bezazepine antipsychotic with unique interactions on dopaminergic system. J. Pharmacol. Exp. Ther. 226:1983;462-468.
19. Kebabian J.W., Calne D.B. Multiple receptors of dopamine. Nature. 227:1979;93-96.
20. Kendler K.S., Bracha H.S., Davis K.L. Dopamine autoreceptor and post-synaptic receptor blocking potency of neuroleptics. Eur. J. Pharmacol. 79:1982;217-223.
21. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev. 21:1997;91-104.
22. Maldonado R., Stinus L., Koob G.F. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261:1992;669-677.
23. Morris B.J., Herz A. Control of opiate receptor number in vivo: stimulation ê-receptor down-regulation and μ-receptor regulation following chronic agonist/antagonist treatment. Neuroscience. 29:1989;433-442.
24. Neilsen M., Klimek V., Hyttel J. Distinct target size of dopamine D-1 and D-2 receptors in rat striatum. Life Sci. 351:1984;325-332.
25. Nestler E.J., Hope B.T., Windnell K.L. Drug addiction: a model for the molecular basis of neural plasticity. Neuron. 11:1993;995-1006.
26. Redmond D.E. Jr., Krystal J.H. Multiple mechanisms of withdrawal from opioid drugs. Annu. Rev. Neurosci. 7:1984;443-478.
27. Rezayat M., Nikfar Sh., Zarrindast M.R. CCK receptor activation may prevent tolerance to morphine in mice. Eur. J. Pharmacol. 254:1994;21-26.
28. Ronnekleiv O.K., Bosch M.A., Cunningham M.J., Wagner E.J., Grady D.K., Kelly M.J. Down-regulation of μ-opioid receptor mRNA in the mediobasal hypothalamus of the female guinea pig following morphine treatment. Neurosci. Lett. 216:1996;129-132.
29. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 32:1980;229-313.
30. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18:1995;463-495.
31. Setler P.E., Sapau H.M., Zirkle C.L., Saunders H.L. The central effects of a novel dopamine agonist. Eur. J. Pharmacol. 50:1978;419-430.
32. Sibley D.R., Monsma F.J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:1992;61-69.
33. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22:1999;521-527.
34. +-stimulated release of acetylcholine from neostriatum. Brain Res. 250:1982;263-270.
35. Stoof J.C., Kebabian J.W. Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 35:1984;2281-2296.
36. Weis O.F., Sriwatanakul K., Alloza J.L., Weintraub M., Lasagna L. Attitudes of patients, housestaff, and nurses toward postoperative analgesic care. Anesth. Analg. 62:1983;70-74.
37. Zarrindast M.R., Farzin D. Nicotine attenuates naloxone-induced jumping behaviour in morphine-dependent mice. Eur. J. Pharmacol. 298:1996;1-6.
38. Zarrindast M.R., Jamshidzadeh A. Inhibitory effect of morphine on yawing induced by cholinoceptor and dopamine D2 receptor activation in rats. Br. J. Pharmacol. 105:1992;675-678.
39. Zarrindast M.R., Zarghi A. Morphine stimulates locomotor activity by an indirect dopaminergic mechanism: possible D-1 and D-2 receptor involvement. Gen. Pharmacol. 23:1992;1221-1225.
40. Zarrindast M.R., Vahedy A., Heidari M.R., Ghazi-Khansari M. On the mechanism(s) of morphine-induced hypothermia. J. Psychopharmacol. 8:1994;222-226.
41. Zarrindast M.R., Mamanpush S.M., Rashidy-pour A. Morphine inhibits dopaminergic and cholinergic induced ejaculation in rats. Gen. Pharmacol. 25:1994;803-808.
42. Zarrindast M.R., Fazli-Tabaei S., Semnanian S., Fathollahi Y. Influence of different adrenoceptor agonists and antagonists on physostigmine-induced yawning in rats. Pharmacol. Biochem. Behav. 62:1999;1-5.
43. Zarrindast M.R., Fazli-Tabaei S., Semnanian S., Fathollahi Y., Yahyavi S.H. Effects of adrenoceptor agents on apomorphine-induced licking behaviour in rats. Pharmacol. Biochem. Behav. 65:2000;275-279.